United States Vaccines Market Size, Share, Growth Opportunities, Future Trends, Top Key Players, and Forecast to 2026

November 2019 | 150 pages | ID: UBB99BA5E56FEN
DPI Research

Abstracts

The United States vaccines market is poised to reach a value of more than US$ 26 billion by 2026.

“United States Vaccines Market Size, Share, Growth Opportunities, Future Trends, Top Key Players, and Forecast to 2026” provides a comprehensive analysis of the fast-evolving, high-growth united states vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the united states vaccines market. The report provides historical market data for 2015 – 2018, and forecasts from 2019 till 2026.

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2026.The report provides clear insight into current and future developments of the united states vaccines market. The report also explores the detailed analysis of the leading 27 vaccines market assessments in the United States from 2015 to 2018 and forecasts to 2026. A comprehensive analysis has been done on market share with percentage of the leading 27 vaccines. The report also details the latest information about the vaccine's pricing trends and regulatory framework of the United States vaccine market.

Key trends in terms of collaboration, partnerships, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also examines the main market growth driving and restraining forces and also gives an all-round future outlook through 2026.

The report concludes with the profiles of the key players in the united states vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, promising vaccines in the clinical development, and recent development.

The major companies dominating this market for its products, services, and continuous product developments are:

• Pfizer
• Merck
• Sanofi Pasteur
• Grifols
• GlaxoSmithKline (GSK)
• Dynavax Technologies Corporation

The following 27 leading vaccines of the united states vaccines market are detailed with market size and seven-years forecast

• Prevnar/Prevnar 13
• Gardasil/Gardasil 9
• Fluzone
• Flublok
• Flucelvax Quadrivalent
• Afluria Quadrivalent
• Fluad
• Varivax
• Menactra
• Proquad
• Pneumovax 23
• Fluarix/FluLaval
• Havrix/Twinrix/Engerix–B
• M–M–R II
• Adacel
• Boostrix
• Bexsero
• Menveo
• Trumenba
• Shingrix
• Pentacel
• Recombivax HB
• Rotateq
• Rotarix
• Pediarix/Infanrix
• Heplisav–B
• TDVAX

Key Topics Covered in the Report:

• The Market Size of the United States Vaccines Market with Seven Years Forecast
• The Market Size of the 27 Leading Vaccines with Seven Years Forecast
• Thoroughly Evaluates Market Share of the 27 Leading Vaccines in the US Vaccines Market
• Provides Comprehensive Insights on the Latest Vaccines Pricing Trends and Analysis
• Detailed Insights of the Regulatory Framework of the US Vaccines Market
• Investigates the Key Growth Drivers and Restraints of the United States Vaccines Market
• Provides Key Trends with Respect to Collaboration, Partnerships, Merger & Acquisition, Distribution, Exclusive and Licensing Agreement
• A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, and Recent Development

The Report Helps Answer the Following Questions:

• What is the current size of the overall united states vaccines market? How much will this market be worth from 2019 to 2026?
• What are the leading vaccines? What are their revenue potentials to 2026?
• Which vaccine provides highest market share?
• What are the main drivers and restraints in the united states vaccines market?
• What are the major deals happenings in the vaccines market?
• What are the united states vaccines pricing trends and analysis?
• What are the various vaccines available in the United States?
• Who are the leading companies and what are their activities, promising vaccines in the clinical development, recent developments, and prospects?

Contents

1. EXECUTIVESUMMARY

2. UNITED STATES VACCINES MARKET SIZE & FORECAST (2015 – 2026)

3. UNITED STATES VACCINES MARKET SHARE & Y–O–Y GROWTH (%), 2017 – 2026

4. UNITED STATES VACCINES MARKET – KEY MARKET DYNAMICS

4.1 Key Market Drivers
4.2 Key Market Inhibitors

5. UNITED STATES LEADING 27 VACCINES MARKET ASSESSMENT & OPPORTUNITY (VALUE),2015 – 2026

5.1 Prevnar/Prevnar
5.2 Gardasil/Gardasil
5.3 Fluzone
5.4 Flublok
5.5 Flucelvax Quadrivalent
5.6 Afluria Quadrivalent
5.7 Fluad
5.8 Varivax
5.9 Menactra
5.10 Proquad
5.11 Pneumovax
5.12 Fluarix/FluLaval
5.13 Havrix/Twinrix/Engerix–B
5.14 M–M–R II
5.15 Adacel
5.16 Boostrix
5.17 Bexsero
5.18 Menveo
5.19 Trumenba
5.20 Shingrix
5.21 Pentacel
5.22 Recombivax HB
5.23 Rotateq
5.24 Rotarix
5.25 Pediarix/Infanrix
5.26 Heplisav–B
5.27 TDVAX
5.28 Other Vaccines

6. UNITED STATES VACCINES PRICING TRENDS & ANALYSIS

7. REGULATORY FRAMEWORK OF THE UNITED STATES VACCINES MARKET

8. MAJOR DEALS AND AGREEMENT HAPPENINGS IN THE VACCINES MARKET

8.1 Collaboration Deal
8.2 Licensing Agreement
8.3 Exclusive Agreement
8.4 Distribution Agreement
8.5 Partnerships

9. KEY PLAYERS IN THE UNITED STATES VACCINES MARKET

9.1 Sanofi Pasteur
  9.1.1 Business Overview
  9.1.2 Promising Vaccines in the Clinical Development
  9.1.3 Recent Development
9.2 GlaxoSmithKline (GSK)
  9.2.1 Business Overview
  9.2.2 Vaccines Portfolio
  9.2.3 Promising Vaccines in the Clinical Development
  9.2.4 Recent Development
9.3 Merck
  9.3.1 Business Overview
  9.3.2 Vaccines Portfolio
  9.3.3 Promising Vaccines in the Clinical Development
9.4 Pfizer
  9.4.1 Business Overview
  9.4.2 Vaccines Portfolio
  9.4.3 Promising Vaccines in the Clinical Development
  9.4.4 Recent Development
9.5 Dynavax Technologies Corporation
  9.5.1 Business Overview
  9.5.2 Vaccines Portfolio
  9.5.3 Promising Vaccines in the Clinical Development
  9.5.4 Recent Development
9.6 Grifols
  9.6.1 Business Overview
  9.6.2 Vaccines Portfolio
  9.6.3 Recent Development

List Of Tables

LIST OF TABLES

Table 3–1: United States Vaccines Market Share & Y–o–Y Growth (Percent), 2017 – 2018
Table 3–2: United States Vaccines Market Share & Y–o–Y Growth Forecast (Percent), 2019 – 2026
Table 6–1: United States Adult Vaccines Price, 2019 – 2020
Table 6–2: United States Adult Influenza Vaccines Price, 2019 – 2020
Table 6–3: United States Pediatric Vaccines Price, 2019 – 2020
Table 6–4: United States Pediatric Influenza Vaccines Price, 2019 – 2020
Table 7–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–1: Merger & Acquisitions in the Vaccines Market
Table 8–2: Collaboration Deal in the Vaccines Market
Table 8–3: Licensing Agreement in the Vaccines Market
Table 8–4: Exclusive Agreement in the Vaccines Market
Table 8–5: Distribution Agreement in the Vaccines Market
Table 8–6: Partnerships in the Vaccines Market
Table 9–1: Sanofi Promising Vaccines in the Clinical Development
Table 9–2: GSK Promising Vaccines in the Clinical Development
Table 9–3: Merck Promising Vaccines in the Clinical Development
Table 9–4: Pfizer Promising Vaccines in the Clinical Development
Table 9–5: Dynavax Technologies Corporation Promising Vaccines in the Clinical Development

List Of Figures

LIST OF FIGURES

Figure 2–1: United States Vaccines Market Size (Million US$),2015 – 2018
Figure 2–2: United States Vaccines Market Size Forecast (Million US$),2019 – 2026
Figure 5–1: United States Prevnar/Prevnar 13 Market Value (Million US$),2015 – 2018
Figure 5–2: United States Prevnar/Prevnar 13 Market Value Forecast (Million US$),2019 – 2026
Figure 5–3: United States Gardasil/Gardasil 9 Market Value (Million US$),2015 – 2018
Figure 5–4: United States Gardasil/Gardasil 9 Market Value Forecast (Million US$),2019 – 2026
Figure 5–5: United States Fluzone Market Value (Million US$),2015 – 2018
Figure 5–6: United States Fluzone Market Value Forecast (Million US$),2019 – 2026
Figure 5–7: United States Fluzone Market Value & Forecast (Million US$),2018 – 2026
Figure 5–8: United States Flucelvax Quadrivalent Market Value (Million US$),2016 – 2018
Figure 5–9: United States Flucelvax Quadrivalent Market Value Forecast (Million US$),2019 – 2026
Figure 5–10: United States Afluria Quadrivalent Market Value (Million US$),2016 – 2018
Figure 5–11: United States Afluria Quadrivalent Market Value Forecast (Million US$),2019 – 2026
Figure 5–12: United States Fluad Market Value (Million US$),2016 – 2018
Figure 5–13: United States Fluad Market Value Forecast (Million US$),2019 – 2026
Figure 5–14: United States Varivax Market Value (Million US$),2015 – 2018
Figure 5–15: United States Varivax Market Value Forecast (Million US$),2019 – 2026
Figure 5–16: United States Menactra Market Value (Million US$),2015 – 2018
Figure 5–17: United States Menactra Market Value Forecast (Million US$),2019 – 2026
Figure 5–18: United States Proquad Market Value (Million US$),2015 – 2018
Figure 5–19: United States Proquad Market Value Forecast (Million US$),2019 – 2026
Figure 5–20: United States Pneumovax 23 Market Value (Million US$),2015 – 2018
Figure 5–21: United States Pneumovax 23 Market Value Forecast (Million US$),2019 – 2026
Figure 5–22: United States Fluarix/FluLaval Market Value (Million US$),2015 – 2018
Figure 5–23: United States Fluarix/FluLaval Market Value Forecast (Million US$),2019 – 2026
Figure 5–24: United States Havrix/Twinrix/Engerix–B Market Value (Million US$),2015 – 2018
Figure 5–25: United States Havrix/Twinrix/Engerix–B Market Value Forecast (Million US$),2019 – 2026
Figure 5–26: United States M–M–R ll Market Value (Million US$),2015 – 2018
Figure 5–27: United States M–M–R ll Market Value Forecast (Million US$),2019 – 2026
Figure 5–28: United States Adacel Market Value (Million US$),2015 – 2018
Figure 5–29: United States Adacel Market Value Forecast (Million US$),2019 – 2026
Figure 5–30: United States Boostrix Market Value (Million US$),2015 – 2018
Figure 5–31: United States Boostrix Market Value Forecast (Million US$),2019 – 2026
Figure 5–32: United States Bexsero Market Value (Million US$),2015 – 2018
Figure 5–33: United States Bexsero Market Value Forecast (Million US$),2019 – 2026
Figure 5–34: United States Menveo Market Value (Million US$),2015 – 2018
Figure 5–35: United States Menveo Market Value Forecast (Million US$),2019 – 2026
Figure 5–36: United States Trumenba Market Value (Million US$),2017 – 2018
Figure 5–37: United States Trumenba Market Value Forecast (Million US$),2019 – 2026
Figure 5–38: United States Shingrix Market Value (Million US$),2017 – 2018
Figure 5–39: United States Shingrix Market Value Forecast (Million US$),2019 – 2026
Figure 5–40: United States Pentacel Market Value (Million US$),2015 – 2018
Figure 5–41: United States Pentacel Market Value Forecast (Million US$),2019 – 2026
Figure 5–42: United States Recombivax HB Market Value (Million US$),2015 – 2018
Figure 5–43: United States Recombivax HB Market Value Forecast (Million US$),2019 – 2026
Figure 5–44: United States Rotateq Market Value (Million US$),2015 – 2018
Figure 5–45: United States Rotateq Market Value Forecast (Million US$),2019 – 2026
Figure 5–46: United States Rotarix Market Value (Million US$),2015 – 2018
Figure 5–47: United States Rotarix Market Value Forecast (Million US$),2019 – 2026
Figure 5–48: United States Pediarix/Infanrix Market Value (Million US$),2015 – 2018
Figure 5–49: United States Pediarix/Infanrix Market Value Forecast (Million US$),2019 – 2026
Figure 5–50: United States Heplisav–B Market Value & Forecast (Million US$),2018 – 2026
Figure 5–51: United States TDVAX Market Value (Million US$),2016 – 2018
Figure 5–52: United States TDVAX Market Value Forecast (Million US$),2019 – 2026
Figure 5–53: United States Other Vaccines Market Value (Million US$),2015 – 2018
Figure 5–54: United States Other Vaccines Market Value Forecast (Million US$),2019 – 2026